Report of Foreign Issuer (6-k)

Date : 07/17/2017 @ 10:18AM
Source : Edgar (US Regulatory)
Stock : Novo Nordisk A/S (NVO)
Quote : 48.79  0.0 (0.00%) @ 8:41AM
Novo Nordisk A S share price Chart

Report of Foreign Issuer (6-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

________________

 

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER

 

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

July 17, 2017

________________

 

NOVO NORDISK A/S

  (Exact name of Registrant as specified in its charter)

 

 

Novo Allé 

DK- 2880, Bagsvaerd 

Denmark

(Address of principal executive offices)

________________

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

 

Form 20-F [X]           Form 40-F [  ]

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes [  ]            No [X]

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________

 

 

 

  

 

Novo Nordisk A/S – Share repurchase programme

 

 

Bagsværd, Denmark, 17 July 2017 – On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 16 billion to be executed during a 12-month period beginning 2 February 2017.

 

Under the programme initiated 3 May 2017, Novo Nordisk will repurchase B shares for an amount up to DKK 4.3 billion in the period from 3 May 2017 to 7 August 2017.

 

Since the announcement as of 11 July 2017, the following transactions have been made under the programme:

 

      Number of
B shares
      Average
purchase price
      Transaction
value, DKK
 
Accumulated, last announcement     10,643,086               2,994,414,082  
11 July 2017     250,000       272.80       68,199,925  
12 July 2017     230,000       275.04       63,259,856  
13 July 2017     240,000       277.34       66,560,701  
14 July 2017     240,000       277.01       66,482,758  
Accumulated under the programme     11,603,086               3,258,917,322  

 

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

 

With the transactions stated above, Novo Nordisk owns a total of 29,192,349 B shares of DKK 0.20, corresponding to 1.2% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,500,000,000 including treasury shares.

 

 

 

Page 2 of 2

 

 

Novo Nordisk expects to repurchase B shares for an amount up to DKK 16 billion during a 12-month period beginning 2 February 2017. As of 17 July 2017, Novo Nordisk has repurchased a total of 28,085,479 B shares equal to a transaction value of DKK 7,258,905,355.

 

 

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,000 people in 77 countries and markets its products in more than 165 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com , Facebook, Twitter, LinkedIn, YouTube

 

Further information

Media:
Anne Margrethe Hauge +45 4442 3450 amhg@novonordisk.com
Ken Inchausti (US) +1 609 786 8316 kiau@novonordisk.com
     
Investors :
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Hanna Ögren +45 3079 8519 haoe@novonordisk.com
Anders Mikkelsen +45 3079 4461 armk@novonordisk.com
Kasper Veje (US) +1 609 235 8567 kpvj@novonordisk.com

 

 

 

 

 

 

 

 

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Internet:
www.novonordisk.com

CVR no:

24 25 67 90

    Company announcement No 55 / 2017

 
 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

 

Date: July 17, 2017

 

NOVO NORDISK A/S

 

Lars Fruergaard Jørgensen

Chief Executive Officer

 

 

Novo Nordisk A S (NYSE:NVO)
Historical Stock Chart

1 Year : From Sep 2016 to Sep 2017

Click Here for more Novo Nordisk A S Charts.

Novo Nordisk A S (NYSE:NVO)
Intraday Stock Chart

Today : Tuesday 26 September 2017

Click Here for more Novo Nordisk A S Charts.

Latest NVO Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V:us D:20170926 12:56:03